filmov
tv
Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population -a cost-effectiveness...
Показать описание
Presented By: Aaron Tan
Speaker Biography: Aaron is currently an Oncology Fellow at the National Cancer Centre Singapore (NCCS), having completed his specialty training in Medical Oncology in Sydney, Australia. He also completed a PhD in cancer drug discovery at The University of Sydney. His current focus is in early phase clinical trials and lung cancer translational research. As an early career researcher, he has received numerous awards and achievements including an International Association for the Study of Lung Cancer (IASLC) Fellowship 2018-2020, ASCO 2018 and ESMO Asia 2019 Merit Awards.
Webinar: Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis
Webinar Abstract: There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsies is an increasingly encountered problem. We compared the performance of targeted NGS panels with traditional assays and correlated the mutational landscape with PD-L1 status in Singaporean patients with the National Lung Profiling (NLP) study.
Speaker Biography: Aaron is currently an Oncology Fellow at the National Cancer Centre Singapore (NCCS), having completed his specialty training in Medical Oncology in Sydney, Australia. He also completed a PhD in cancer drug discovery at The University of Sydney. His current focus is in early phase clinical trials and lung cancer translational research. As an early career researcher, he has received numerous awards and achievements including an International Association for the Study of Lung Cancer (IASLC) Fellowship 2018-2020, ASCO 2018 and ESMO Asia 2019 Merit Awards.
Webinar: Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis
Webinar Abstract: There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsies is an increasingly encountered problem. We compared the performance of targeted NGS panels with traditional assays and correlated the mutational landscape with PD-L1 status in Singaporean patients with the National Lung Profiling (NLP) study.
1:03:21
0:01:57
0:02:30
0:01:49
0:01:22
1:08:57
0:00:16
0:03:37
1:04:32
0:56:17
0:01:19
0:59:42
0:59:24
0:46:47
0:24:59
1:43:56
1:09:04
0:01:28
1:05:35
0:36:39
0:59:15
0:22:51
0:02:01
0:16:03